Early Acute Allograft Dysfunction During the Second Week Following ABO-Incompatible Living Donor Kidney Transplantation: A Case Report

by kh-ima-admin | November 11, 2026 9:06 am

Abstract

Background:

ABO-incompatible (ABOi) kidney transplantation is an established option for patients with an ABO-incompatible living donor. Despite successful desensitisation, early allograft dysfunction may occur and requires evaluation for immunological and non-immunological causes.

Case presentation:

A 48-year-old man with end-stage kidney disease and longstanding hypertension underwent ABOi living donor kidney transplantation from his wife (recipient O positive; donor B positive). Pre-transplant T- and B-cell complement-dependent cytotoxicity and flow-cytometry crossmatches were negative. Following immunoadsorption, anti-B titres immediately before transplantation were IgG 1:2 and IgM 1:4. Initial graft function was satisfactory, with serum creatinine decreasing to approximately 1.08 mg/dL by postoperative day (POD) 6. On approximately POD 9, he developed tremors, graft-site tenderness and decreased urine output, with serum creatinine rising to 2.14 mg/dL. Anti-B titres increased, reaching IgG 1:16 and IgM 1:8, while creatinine peaked at approximately 3.73 mg/dL. Donor-specific antibody (DSA) testing was negative. He was treated with pulse intravenous corticosteroids and two sessions of therapeutic plasma exchange, followed by intravenous immunoglobulin (IVIG). Tacrolimus exposure was reassessed and the dose adjusted; a concomitant Enterococcus faecalis urinary infection was treated with teicoplanin. Graft function and anti-B titres improved following treatment, and renal allograft biopsy was deferred because of the favourable clinical and biochemical response.

Conclusion:

This case highlights the importance of integrated monitoring after ABOi transplantation. Anti-ABO antibody rebound accompanied by graft dysfunction warrants prompt evaluation, but neither titre elevation nor creatinine rise alone establishes ABMR. Negative DSA testing and the absence of biopsy findings should be considered when interpreting the episode.

Keywords: ABO-incompatible kidney transplantation; acute allograft dysfunction; anti-B isohaemagglutinin; DSA; immunoadsorption; plasma exchange; IVIG.

1. Introduction

ABO-incompatible kidney transplantation has expanded the living-donor pool for patients with end-stage kidney disease. The principal immunological barrier is the presence of naturally occurring recipient anti-A or anti-B antibodies directed against ABO antigens expressed on graft vascular endothelium. Desensitisation approaches, including immunoadsorption and therapeutic plasma exchange, reduce circulating antibody levels before transplantation (1,2).

After transplantation, some ABO-incompatible grafts develop accommodation, in which graft function is maintained despite the presence or reappearance of circulating anti-ABO antibodies. Therefore, antibody titre changes alone do not establish graft injury. A rise in titres accompanied by acute graft dysfunction warrants evaluation for rejection and other causes, including acute tubular injury, calcineurin-inhibitor toxicity, thrombotic microangiopathy, infection, and vascular or urological complications (1,4).

We report a case of early acute allograft dysfunction during the second postoperative week following ABO-incompatible living donor kidney transplantation, associated with a rise in anti-B titres and followed by improvement after treatment.

2. Case presentation

2.1 Recipient and donor characteristics

A 48-year-old man with chronic kidney disease of approximately eight years’ duration and end-stage kidney disease requiring maintenance haemodialysis since November 2025 was evaluated for living donor kidney transplantation. His medical history included systemic hypertension for approximately 12 years and dyslipidaemia. His wife was the living donor. The recipient was blood group O positive and the donor was B positive.

2.2 Pre-transplant immunological evaluation and desensitisation

Pre-transplant T-cell and B-cell complement-dependent cytotoxicity crossmatches and flow-cytometry crossmatches were negative. HLA matching was documented as 9/18. Single-antigen bead testing was recorded as Class I negative, with low-level Class II reactivity in the pre-transplant record; the specificity and donor relevance should be confirmed from the laboratory report. The pre-desensitisation anti-B titres appear to have been IgG 1:128 and IgM 1:128. Following immunoadsorption, the ABOi kidney transplant case report Page 2 preoperative anti-B titres were reduced to IgG 1:2 and IgM 1:4.

2.3 Transplantation and initial graft function

The patient underwent living donor kidney transplantation from his wife on 20 October 2026. The immediate postoperative course was initially satisfactory, with improving graft function. Serum creatinine was approximately 1.08 mg/dL by POD 6.

2.4 Presentation with acute graft dysfunction

On approximately POD 9, the patient developed tremors, tenderness over the graft site and decreased urine output. Serum creatinine increased to approximately 2.14 mg/dL. Serial anti-B isohaemagglutinin titres showed an increase, with IgG 1:8 and IgM 1:4 recorded around POD 9, followed by a peak of IgG 1:16 and IgM 1:8 in a subsequent measurement. Serum creatinine continued to rise, reaching approximately 3.29 mg/dL on POD 10 and 3.73 mg/dL on POD 11. DSA testing performed during the evaluation was negative.

2.5 Diagnostic evaluation

Transplant Doppler ultrasonography documented patent renal vessels without evidence of significant stenosis or occlusion. Mildly increased intrarenal resistive indices, approximately 0.7–0.8, and a mild perinephric collection were noted. Urine culture grew Enterococcus faecalis; blood cultures showed no growth. Tacrolimus trough concentrations were monitored and the dose was adjusted. DSA testing was negative. In view of the subsequent clinical and biochemical improvement following treatment, renal allograft biopsy was deferred. Consequently, no histopathological diagnosis was established during this episode.

2.6 Management

Given the progressive graft dysfunction occurring alongside an increase in anti-B titres, the patient received pulse intravenous corticosteroids and two sessions of therapeutic plasma exchange. IVIG was administered after completion of plasma exchange. Tacrolimus exposure was reassessed and the dose adjusted. The concomitant Enterococcus faecalis urinary infection was treated with teicoplanin (Targocid), according to the clinical record.

2.7 Clinical outcome

Following treatment, anti-B titres declined, with subsequent values recorded as IgG 1:8 and IgM 1:4, followed by IgG 1:4 and IgM 1:2. Serum creatinine improved from a peak of approximately 3.73 mg/dL to 2.47 mg/dL on POD 13 and approximately 1.79 mg/dL on POD 14. With improvement in urine output and graft function, biopsy was deferred and the patient was discharged with improving graft function. Longer-term graft function was not available for this report.

3. Summary of clinical timeline

Time point Creatinine Anti-B titres / clinical events
Pre-transplant – After immunoadsorption: IgG 1:2; IgM 1:4
POD 6 (approx.) 1.08 mg/dL Initial satisfactory graft function
POD 9 (approx.) 2.14 mg/dL Tremors, graft-site tenderness, decreased urine output; IgG 1:8, IgM 1:4; DSA negative
POD 10 (approx.) 3.29 mg/dL Anti-B titres subsequently reported to peak at IgG 1:16, IgM 1:8
POD 11 (approx.) 3.73 mg/dL Peak creatinine; pulse steroids and plasma exchange administered
After plasma exchange IVIG administered after completion of plasma exchange
POD 13 (approx.) 2.47 mg/dL Improving graft function; anti-B titres declining
POD 14 (approx.) 1.79 mg/dL Continued improvement; biopsy deferred

Note: Values and postoperative-day assignments are transcribed from the available handwritten follow-up records and should be checked against the original laboratory reports before submission.

4. Discussion

4.1 ABO-incompatible transplantation and accommodation

ABO antigens are expressed on renal vascular endothelial cells. Recipient anti-ABO antibodies may bind to donor antigens and potentially activate complement and endothelial injury. Desensitisation reduces circulating antibodies before transplantation. In this patient, immunoadsorption reduced the preoperative anti-B titres to IgG 1:2 and IgM 1:4 (1,2).

Accommodation describes graft function maintained despite the presence or reappearance of circulating anti-ABO antibodies. Thus, antibody rebound is not synonymous with rejection and must be interpreted in the context of graft function and other investigations (1,4).

4.2 Interpretation of anti-B antibody rebound and negative DSA

The rise in anti-B titres during the second postoperative week coincided with worsening graft function. This temporal relationship raises concern for an ABO antibody-associated process. DSA testing was negative, which argues against detectable HLA donor-specific antibody at the time of testing; however, a negative HLA-DSA result does not exclude anti-ABO antibody-mediated injury. Isohaemagglutinin titres are influenced by assay methodology, laboratory technique, sampling interval and treatment timing. Titres should be interpreted using the same validated method and alongside clinical findings, HLA-DSA testing and, when available, histopathology (1,2,4).

ABMR cannot be diagnosed from anti-ABO titre elevation and creatinine rise alone. The Banff diagnostic framework requires appropriate tissue injury and evidence of antibody interaction with the endothelium, together with serological or accepted molecular evidence, as applicable. In ABO-incompatible grafts, C4d staining may occur in the absence of rejection and must be interpreted in the full clinicopathological context (3,4).

4.3 Differential diagnosis of early allograft dysfunction

The differential diagnosis includes ABMR, T-cell-mediated rejection, acute tubular injury, calcineurin-inhibitor toxicity, thrombotic microangiopathy, infection, and vascular or urological complications. Doppler findings in this case did not identify major vascular stenosis or occlusion. Tacrolimus exposure was reviewed and the dose adjusted. Urine culture grew Enterococcus faecalis, which was treated with teicoplanin. A urinary infection may coexist with another cause of graft dysfunction and should not automatically be assumed to explain the full creatinine rise.

Renal allograft biopsy is important in persistent or unexplained graft dysfunction because it can distinguish rejection from acute tubular injury, drug toxicity and thrombotic microangiopathy. In this patient, biopsy was deferred because graft function improved following treatment. This limits definitive attribution of the episode to ABMR or another specific histopathological process.

4.4 Treatment and response

The patient received pulse intravenous corticosteroids and two sessions of therapeutic plasma exchange, followed by IVIG. Tacrolimus exposure was adjusted, and the concomitant urinary infection was treated. The subsequent fall in anti-B titres and improvement in serum creatinine are clinically encouraging. However, because multiple interventions were administered during the same episode and biopsy was not performed, the response cannot establish the precise mechanism of injury or the independent effect of any single intervention.

4.5 Limitations

The principal limitation is the absence of a renal allograft biopsy, which was deferred because of clinical and biochemical improvement. Therefore, rejection, acute tubular injury, calcineurin-inhibitor toxicity and other histopathological causes could not be definitively distinguished. Although HLA-DSA testing was negative, this does not exclude an ABO antibody-associated process. The case should consequently be interpreted as acute graft dysfunction temporally associated with anti-B antibody rebound, rather than confirmed biopsy-proven ABMR.

4.6 Clinical implications

This case emphasises that satisfactory initial graft function and successful pre-transplant desensitisation do not eliminate the possibility of early post-transplant dysfunction. Monitoring should integrate urine output, serum creatinine, anti-ABO titres, tacrolimus levels, DSA testing, microbiology, Doppler imaging and, when indicated, graft biopsy. Graft-site tenderness and oliguria accompanying biochemical deterioration warrant prompt assessment.

5. Conclusion

Acute allograft dysfunction during the second postoperative week following ABO-incompatible kidney transplantation is a complex clinical problem. In this patient, graft dysfunction developed after initially satisfactory function and coincided with a rise in anti-B antibody titres, while HLA-DSA testing was negative. Treatment with pulse intravenous corticosteroids and two sessions of plasma exchange, followed by IVIG, alongside tacrolimus dose adjustment and treatment of concomitant Enterococcus faecalis urinary infection, was followed by improvement in graft function. Biopsy was deferred because of this favourable response. The case highlights the importance of integrated clinical, immunological, microbiological and histopathological assessment. The available information supports an association between anti-B antibody rebound and graft dysfunction but does not establish biopsy-proven ABMR.

6. Learning points

  • Successful pre-transplant desensitisation does not eliminate the possibility of post-transplant anti-ABO antibody rebound.
  • A rise in anti-ABO titres must be interpreted alongside graft function and is not, by itself, diagnostic of ABMR.
  • Negative HLA-DSA testing does not exclude an ABO antibody-associated process.
  • Tremors, graft-site tenderness and decreased urine output in the early postoperative period warrant prompt assessment of graft function and drug exposure.
  • When clinically indicated, graft biopsy is important for distinguishing rejection from other causes of allograft injury.

7. References

  1. Maritati F, Bini C, Cuna V, Tondolo F, Lerario S, Grandinetti V, et al. Current perspectives in ABO-incompatible kidney transplant. J Inflamm Res. 2022;15:3095–3103. doi:10.2147/JIR.S360460.
  2. Bhalla A, Anil Kumar B, Chauhan M, Das P, Gandhi B, Hegde U, et al. ABO-incompatible kidney transplantation: Indian working group recommendations. Indian J Transplant. 2019;13(4):252. doi:10.4103/ijot.ijot_39_19.
  3. Naesens M, Roufosse C, Haas M, Lefaucheur C, Mannon RB, Adam BA, et al. The Banff 2022 Kidney Meeting Report: Reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics. Am J Transplant.
    2024;24(3):338–349. doi:10.1016/j.ajt.2023.10.016.
  4. Castrezana Lopez K, Weidmann L, Harmacek D, Roessler F, George B, von Moos S, et al. Antibody-mediated rejection in ABO-incompatible kidney transplantation. Nephrol Dial Transplant. 2026;41(5):956–968. doi:10.1093/ndt/gfaf224.
  5. Schinstock CA, Mannon RB, Budde K, et al. Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the Transplantation Society Working Group. Transplantation. 2020;104(5).

Dr C. Chaitra,
Postgraduate in Nephrology.

Kauvery Hospital, Chennai.[1]

Dr R. Balasubramaniyam,
Chief Nephrologist.

Kauvery Hospital, Chennai.[1]

Endnotes:
  1. Kauvery Hospital, Chennai.: https://www.kauveryhospital.com/

Source URL: https://www.kauveryhospital.com/ima-journal/ima-journal-november-2026/early-acute-allograft-dysfunction-during-the-second-week-following-abo-incompatible-living-donor-kidney-transplantation-a-case-report/